Novartis in-licenses Incyte compounds

By BC Staff | Nov 25, 2009 | 10:49 PM GMT

Incyte Corp. (NASDAQ:INCY) was up $0.74 (10%) to $8.46 on Wednesday after granting Novartis

Read the full 146 word article

How to gain access

Continue reading with a
two-week free trial.